These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26139569)

  • 1. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.
    Akinci B; Koseoglu FD; Onay H; Yavuz S; Altay C; Simsir IY; Ozisik S; Demir L; Korkut M; Yilmaz N; Ozen S; Akinci G; Atik T; Calan M; Secil M; Comlekci A; Demir T
    Metabolism; 2015 Sep; 64(9):1086-95. PubMed ID: 26139569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum adiponectin and leptin levels in patients with lipodystrophies.
    Haque WA; Shimomura I; Matsuzawa Y; Garg A
    J Clin Endocrinol Metab; 2002 May; 87(5):2395. PubMed ID: 11994394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
    Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
    Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature.
    Hosokawa M; Shibata H; Hosokawa T; Irie J; Ito H; Hasegawa T
    J Pediatr Endocrinol Metab; 2019 May; 32(5):537-541. PubMed ID: 31075084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy for the Diabetologist-What to Look For.
    Patni N; Garg A
    Curr Diab Rep; 2022 Sep; 22(9):461-470. PubMed ID: 35821558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy.
    Altay C; Seçil M; Adıyaman SC; Özgen Saydam B; Demir T; Akıncı G; Simsir IY; Eren E; Temeloğlu Keskin E; Demir L; Onay H; Topaloğlu H; Sarer Yürekli B; Özdemir Kutbay N; Gen R; Akıncı B
    Turk J Gastroenterol; 2020 Aug; 31(8):588-595. PubMed ID: 32915147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
    Polyzos SA; Perakakis N; Mantzoros CS
    Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy.
    Lüdtke A; Genschel J; Brabant G; Bauditz J; Taupitz M; Koch M; Wermke W; Worman HJ; Schmidt HH
    Am J Gastroenterol; 2005 Oct; 100(10):2218-24. PubMed ID: 16181372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency.
    Antuna-Puente B; Boutet E; Vigouroux C; Lascols O; Slama L; Caron-Debarle M; Khallouf E; Lévy-Marchal C; Capeau J; Bastard JP; Magré J
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1463-8. PubMed ID: 20097706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature.
    Misra A; Peethambaram A; Garg A
    Medicine (Baltimore); 2004 Jan; 83(1):18-34. PubMed ID: 14747765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study.
    Akinci B; Oral EA; Neidert A; Rus D; Cheng WY; Thompson-Leduc P; Cheung HC; Bradt P; Foss de Freitas MC; Montenegro RM; Fernandes VO; Cochran E; Brown RJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5120-5135. PubMed ID: 31314093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa.
    Ceccarini G; Pelosini C; Paoli M; Tyutyusheva N; Magno S; Gilio D; Palladino L; Sessa MR; Bertelloni S; Santini F
    J Endocrinol Invest; 2024 Aug; 47(8):1881-1886. PubMed ID: 38358463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey.
    Akinci B; Onay H; Demir T; Ozen S; Kayserili H; Akinci G; Nur B; Tuysuz B; Nuri Ozbek M; Gungor A; Yildirim Simsir I; Altay C; Demir L; Simsek E; Atmaca M; Topaloglu H; Bilen H; Atmaca H; Atik T; Cavdar U; Altunoglu U; Aslanger A; Mihci E; Secil M; Saygili F; Comlekci A; Garg A
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2759-67. PubMed ID: 27144933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.